BHC Bausch Health Companies Inc
XNYS
8.15
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BHC
$8.15
—
Key stats
$8.15
- 52-Week Range
- $4.33 – $9.04
- YTD
- +13.11%
- IV Rank (30D)
- 38.7
- Straddle Price
- $2.45
- P/C Vol Ratio
- 0.11
- Market Cap
- $3.0B
- Open
- $7.86
- Day Range
- $7.86 – $8.20
- Volume
- 1,597,568
- Prev Close
- $7.96
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.95% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.95% (VRP-adj) |
| WACC | 5.78% |
| Volatility Risk Premium | +167.1pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +5.2% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.05 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $1.9B |
| Return on Equity (TTM) | 63.3% |
| Book / Price | -11.3% |
| Gross Margin (TTM) | 72.6% |
| FCF Margin (TTM) | 16.8% |
| Quality Score | 4/6 — high quality (12y DCF) |
| SMA 50 | $6.36 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $6.88 |
| Bollinger Width / SMA20 | 800.0% (drives anchor stability) |
| Net Debt | $17.3B |
| Market Cap | $3B |
Peers used for multiples: ALV, GIB, LULU, NVS, SEDG, TEAM
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$70.00
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $141.48 | 30% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 14.6× · 3 peers |
| Peer EV/EBITDA | $148.86 | 14% | median 16.5× · 4 peers |
| Peer P/B | n/a | 0% | median 4.3× · 5 peers |
| Peer P/S | $42.94 | 9% | median 1.4× · 5 peers |
| Market Anchor (SMA50) | $6.36 | 47% | stability 78% (BB-width) |
| Options Expected (B-L 30d) | $8.23 | 0% | 5 strikes · skew +1.02 |
As of 2026-11-06 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $3.0B
- Employees
- 20,300
- List Date
- 1994-03-31
- CIK
- 0000885590
- Headquarters
- Quebec, A8
- Homepage
- https://www.bauschhealth.com
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 19.33% | -11.59% | 22.61% | 0.90% | -6.42% | -20.39% | 0.74% |
| Feb | 21.64% | -3.95% | 18.90% | 17.67% | 2.20% | 2.95% | 9.90% |
| Mar | -0.03% | -2.48% | -12.15% | 7.28% | -9.76% | -9.24% | -4.40% |
| Apr | 1.45% | -17.49% | -5.51% | -15.77% | -15.20% | 2.51% | -8.33% |
| May | 2.36% | -48.44% | 9.32% | -25.03% | -14.53% | -5.13% | -13.58% |
| Jun | -8.46% | -12.64% | -2.44% | 10.11% | 48.66% | -7.16% | 4.68% |
| Jul | -2.69% | -45.84% | 24.17% | -14.95% | -13.25% | 42.95% | -1.60% |
| Aug | -1.75% | 30.07% | -11.93% | -2.79% | 29.95% | -9.00% | 5.76% |
| Sep | -3.47% | 4.55% | -2.84% | 34.43% | -16.02% | -9.89% | 1.13% |
| Oct | -1.82% | -7.54% | -16.22% | 11.25% | 6.04% | 43.11% | 5.80% |
| Nov | -16.44% | 1.88% | 0.85% | -14.42% | -6.75% | 1.49%* | -5.57% |
| Dec | 20.04% | -18.44% | 8.97% | 3.07% | -1.42% | -- | 2.44% |
| Total | 25.37% | -82.58% | 26.26% | -3.41% | -14.18% | 14.34% | -5.70% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $6.99
SMA 50: $6.39
SMA 200: $5.73
Current: $8.13
EMA 12: $7.63
EMA 26: $7.05
MACD: 0.5787 | Signal: 0.1340
BULLISH
ADX (14): 34.81
TREND
+DI: 40.42
−DI: 15.81
Momentum Oscillators
RSI (14): 66.09
NEUTRAL
Stoch %K: 68.42
Stoch %D: 69.74
Williams %R: -32.06
Volume & Volatility
BB Upper: $8.91
BB Lower: $5.06
NEUTRAL
OBV: 126,244,642
Vol SMA 20: 4,541,565
Vol ROC: -37.79%
ATR: $0.41
True Range: $0.33
HV 20: 105.9%
HV 30: 86.9%
HV 60: 69.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-07T00:00:00 – 2026-11-05T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Technical indicators suggest a range-bound market with potential for consolidation
- News sentiment is generally positive, but lacks strong catalysts for significant moves
- Beta analysis indicates moderate volatility, aligned with the overall market
Primary Risks:
- Overbought RSI and Bollinger Bands indicating potential for near-term pullback
- Options market suggests a 27-DTE expected move of $0.62, which could impact short-term performance
Investment Thesis:
BHC is trading within a range-bound market, with technical indicators suggesting consolidation rather than significant directional moves. News sentiment is generally positive, but lacks strong catalysts for growth. As such, the stock presents a moderate-risk opportunity for investors seeking to balance their portfolios.
Recent News Sentiment Impact:
- Positive news headlines (Why Bausch Health Companies Was Crawling Higher This Week and Dermatology Devices Market to Reach $25.6 Billion by 2030) have contributed to the overall positive sentiment
- Neutral news headlines (Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036) have not significantly impacted the analysis
Technical Analysis
Trend Direction:
- Short-term: Range-bound (1-4 weeks)
- Medium-term: Consolidation (1-3 months)
- Long-term: Uptrend (3-12 months)
Support/Resistance Levels:
- Resistance: $5.81 (Bollinger Bands upper band)
- Support: $5.24 (Bollinger Bands lower band) and $5.44 (SMA 50)
Momentum Signals:
- RSI interpretation: Neutral (48.49), indicating no strong buy or sell signals
- MACD signal: Bearish, suggesting potential for a short-term pullback
- Bollinger Bands position: Neutral, indicating consolidation rather than breakout
Volume Analysis:
- Volume trends suggest moderate institutional interest and increasing participation in the market
- Recent volume activity is moderate, indicating no significant buying or selling pressure
News & Sentiment Analysis
Recent Headlines Summary:
- Positive news headlines highlighting growth opportunities in various markets
- Neutral news headlines providing general market commentary and routine announcements
Sentiment Assessment:
- Aggregate sentiment: POSITIVE (60% positive, 20% neutral, 20% negative)
Catalyst Identification:
- No strong catalysts are currently driving the stock price; consolidation is likely to continue
Market Narrative:
- News sentiment aligns with technical signals, suggesting a range-bound market with potential for consolidation
Risk & Volatility Assessment
Beta Interpretation:
- Beta: 0.93 (vs SPY), indicating moderate volatility and correlation with the overall market
Volatility Regime:
- Current volatility is high relative to historical levels, suggesting increased risk
Options Market Signals:
- IV rank: 30.0% (Medium), indicating historically medium-high volatility
- Put/call ratios: Neutral sentiment, with equal buying and selling pressure
- Unusual activity: None significant
Downside Protection:
- Support levels: $5.24 (Bollinger Bands lower band) and $5.44 (SMA 50)
- Risk management considerations: Stop-loss levels should be set near the recent lows, with position sizing adjusted accordingly
Market Context & Positioning
Sector Performance:
- The healthcare sector has been performing well overall, with some stocks experiencing growth opportunities
Institutional Activity:
- Moderate institutional interest and increasing participation in the market suggest a potential for further range-bound trading
Correlation Analysis:
- Stock moves relatively closely to the overall market (R-squared interpretation: 0.79), indicating moderate correlation
Relative Valuation:
- The stock is positioned within a trading range, with no strong catalysts driving price movements; relative valuation suggests the stock is fairly valued
Key Levels & Action Items
Critical Price Levels:
- Support: $5.24 (Bollinger Bands lower band) and $5.44 (SMA 50)
- Resistance: $5.81 (Bollinger Bands upper band)
Breakout/Breakdown Levels:
- Breakout above the Bollinger Bands upper band would suggest a strong buy signal, while a breakdown below the lower band would indicate a strong sell signal
Time-Sensitive Catalysts:
- No significant earnings or product launches are scheduled in the near term; consolidation is likely to continue
Risk Management:
- Stop-loss levels should be set near recent lows, with position sizing adjusted accordingly
- Investors may consider reducing their exposure to the stock if it breaks below the Bollinger Bands lower band
Generated
News
All BHC news →
CEO highlights $1B EBITDA milestone and $521M debt reduction.
Earnings History
17 of 24 under expected move
Avg Expected Move
8.47%
Avg Actual Move
5.68%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-13 | After-Close | 3.88% | 2.36% | 0.61x | Within |
| 2021-05-04 | After-Close | 4.01% | 0.32% | 0.08x | Within |
| 2021-08-03 | After-Close | 3.71% | 5.30% | 1.43x | Exceeded |
| 2021-11-02 | After-Close | 4.68% | 5.33% | 1.14x | Exceeded |
| 2022-02-23 | After-Close | 3.71% | 1.09% | 0.29x | Within |
| 2022-04-28 | After-Close | 4.66% | 3.70% | 0.79x | Within |
| 2022-08-09 | After-Close | 13.13% | 9.07% | 0.69x | Within |
| 2022-11-03 | After-Close | 5.74% | 8.84% | 1.54x | Exceeded |
| 2023-02-23 | After-Close | 3.86% | 2.84% | 0.74x | Within |
| 2023-05-04 | After-Close | 5.77% | 1.02% | 0.18x | Within |
| 2023-08-03 | After-Close | 4.78% | 3.72% | 0.78x | Within |
| 2023-11-02 | After-Close | 4.63% | 3.13% | 0.68x | Within |
| 2024-02-22 | After-Close | 3.87% | 1.29% | 0.33x | Within |
| 2024-05-02 | After-Close | 3.21% | 3.34% | 1.04x | Exceeded |
| 2024-08-01 | Pre-Market | 11.86% | 1.16% | 0.10x | Within |
| 2024-10-30 | After-Close | 10.10% | 12.61% | 1.25x | Exceeded |
| 2025-02-19 | After-Close | 10.29% | 10.29% | 1.00x | Within |
| 2025-04-30 | After-Close | 10.38% | 0.00% | 0.00x | Within |
| 2025-07-30 | After-Close | 9.78% | 7.82% | 0.80x | Within |
| 2025-10-29 | After-Close | 8.47% | 12.03% | 1.42x | Exceeded |
| 2026-01-13 | Pre-Market | 5.01% | 0.13% | 0.03x | Within |
| 2026-04-29 | After-Close | 30.41% | 2.33% | 0.08x | Within |
| 2026-07-29 | After-Close | 5.34% | 28.85% | 5.40x | Exceeded |
| 2026-10-28 | Pre-Market | 32.09% | 9.67% | 0.30x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
BHC Options Activity & IV Rank
BHC IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 82.7%
7-DTE IV: 66.4%
Expected Move: $2.45
7-DTE Move: $0.62
Days to Exp: 28 (2026-12-04)
Options Flow
Call Volume: 19
Put Volume: 2
P/C Volume: 0.105
BULLISH
Call OI: 97
Put OI: 2
P/C OI: 0.021
Total OI: 99
ATM Options Pricing
ATM Call: $0.55
ATM Put: $1.90
Call %: 6.7%
Put %: 23.3%
Chain Summary
Chain Volume: 34,694
Chain OI: 164,149
Last Updated: 11/6/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 93rd percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
93%
vs own history
GEX tilt
+0.71
OI-weighted, today
Vanna tilt
+0.11
δ-sensitivity to IV
Charm tilt
-0.16
δ-decay vs time
? What is this?
· 30 ATM contracts, 16k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM 63.4% / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM 50.5% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)11.1LowNov 6
IV Rank (30 DTE)38.7MediumNov 6
Straddle Price (30 DTE)$2.45Nov 6
Beta Analysis
Risk Metrics
Beta: 1.0413
Alpha: 26.96%
Correlation: 0.2247
R-Squared: 5.0%
Stock Volatility: 62.9%
Market Volatility: 13.6%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own BHC
8 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Paulson & Co. Family office John Paulson | $361.2M | #4 of 8 | 0.0% | 13F | |
| Point72 Hedge fund Steve Cohen | $11.0M | #732 of 1945 | +65.6% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $6.5M | #1299 of 3138 | -15.9% | 13F | |
| Citadel Hedge fund Ken Griffin | $5.4M | #2027 of 6285 | +21.1% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $5.4M | #2014 of 3716 | +150.7% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $4.3M | #513 of 997 | +29.2% | 13F | |
| Icahn Capital / Icahn Enterprises Family office Carl Icahn, Brett Icahn | $1.8M | #14 of 15 | — | Form 4 · Director | |
| Rockefeller Capital Management Family office Rockefeller family | $5K | #4221 of 4729 | +722.1% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BHC Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 378,350,000 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
18 filers$24.58M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $5.14M | 20.91% | 2026-06-30 |
| 2 | Deutsche Bank AG Custodian | $4.93M | 20.06% | 2026-06-30 |
| 3 | SIG North Trading, ULC | $4.36M | 17.74% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $2.73M | 11.12% | 2026-06-30 |
| 5 | Fore Capital, LLC | $1.73M | 7.02% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $1.43M | 5.80% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $983.44K | 4.00% | 2025-09-30 |
| 8 | Sequoia Financial Advisors, LLC | $879.02K | 3.58% | 2026-06-30 |
| 9 | Citadel Advisors LLC Custodian | $711.89K | 2.90% | 2026-06-30 |
| 10 | National Bank of Canada Custodian | $461.75K | 1.88% | 2026-06-30 |
| 11 | IMC-Chicago, LLC Custodian | $311.08K | 1.27% | 2026-06-30 |
| 12 | TRUIST FINANCIAL CORP Custodian | $283.92K | 1.16% | 2026-09-30 |
| 13 | Endure Capital Management, LLC | $210.51K | 0.86% | 2026-06-30 |
| 14 | Walleye Trading LLC | $178.47K | 0.73% | 2026-06-30 |
| 15 | WOLVERINE ASSET MANAGEMENT LLC | $104.02K | 0.42% | 2026-06-30 |
| 16 | Jane Street Group, LLC Custodian | $82.82K | 0.34% | 2026-06-30 |
| 17 | Walleye Capital LLC | $56.70K | 0.23% | 2026-06-30 |
| 18 | JPMorgan Chase & Co Custodian | $970 | <0.01% | 2026-06-30 |
17 filers$49.75M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Lombard Odier Asset Management (USA) Corp | $19.72M | 39.63% | 2026-06-30 |
| 2 | Barclays PLC Custodian | $8.13M | 16.35% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $6.90M | 13.88% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $3.66M | 7.36% | 2026-06-30 |
| 5 | WOLVERINE ASSET MANAGEMENT LLC | $2.68M | 5.39% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $2.51M | 5.04% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $1.32M | 2.66% | 2025-09-30 |
| 8 | Walleye Trading LLC | $1.30M | 2.61% | 2026-06-30 |
| 9 | Caption Management, LLC | $827.75K | 1.66% | 2026-06-30 |
| 10 | Jane Street Group, LLC Custodian | $785.84K | 1.58% | 2026-06-30 |
| 11 | SIG North Trading, ULC | $576.32K | 1.16% | 2026-06-30 |
| 12 | Simplex Trading, LLC Custodian | $440.74K | 0.89% | 2026-06-30 |
| 13 | Crawford Fund Management, LLC | $394.40K | 0.79% | 2026-06-30 |
| 14 | IMC-Chicago, LLC Custodian | $213.96K | 0.43% | 2026-06-30 |
| 15 | HAP TRADING, LLC | $212.06K | 0.43% | 2025-09-30 |
| 16 | National Bank of Canada Custodian | $50.27K | 0.10% | 2026-06-30 |
| 17 | Walleye Capital LLC | $23.17K | 0.05% | 2026-06-30 |
BHC Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Sandra Leung | Director | Award (A) | +5,789 | $5.83 | $33.7K | EDGAR |
| 2026-10-02 | Amy B Wechsler | Director | Award (A) | +1,179 | $5.83 | $6.9K | EDGAR |
| 2026-10-02 | John Paulson | Director | Award (A) | +10,720 | $5.83 | $62.5K | EDGAR |
| 2026-08-20 | Aimee J. Lenar | President, US Pharma | Sell (S) | −36,827 | $7.03 | -$258.9K | EDGAR |
| 2026-07-20 | Aimee J. Lenar | President, US Pharma | Tax (F) | −5,260 | $4.83 | -$25.4K | EDGAR |
| 2026-07-17 | Aimee J. Lenar | President, US Pharma | Tax (F) | −23,395 | $4.89 | -$114.4K | EDGAR |
| 2026-07-15 | Steven Hyosig Lee | SVP, Controller & CAO | Tax (F) | −3,125 | $4.75 | -$14.8K | EDGAR |
| 2026-07-02 | Sandra Leung | Director | Award (A) | +6,845 | $4.93 | $33.7K | EDGAR |
| 2026-07-02 | Amy B Wechsler | Director | Award (A) | +1,394 | $4.93 | $6.9K | EDGAR |
| 2026-07-02 | John Paulson | Director | Award (A) | +12,677 | $4.93 | $62.5K | EDGAR |
| 2026-05-26 | Frank D. Lee | Director | Award (A) | +45,871 | — | EDGAR | |
| 2026-05-26 | Christian A Garcia | Director | Award (A) | +45,871 | — | EDGAR | |
| 2026-05-26 | Michael Goettler | Director | Award (A) | +45,871 | — | EDGAR | |
| 2026-05-26 | Sandra Leung | Director | Award (A) | +45,871 | — | EDGAR | |
| 2026-05-26 | Robert N Power | Director | Award (A) | +45,871 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
BHC Insider Holdings
19 insiders · @ $8.13
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | John Paulson | Director | 73,696,831 | $599.16M | $452.88M | 48 | 2026-10-02 |
| 2 | PAULSON & CO. INC. | 10%+ Owner | 73,255,869 | $595.57M | $15.62M | 1 | 2025-11-28 |
| 3 | Thomas Appio | Chief Executive Officer | 3,453,236 | $28.07M | $584.0K | 35 | 2026-03-03 |
| 4 | Seana Carson | EVP, General Counsel | 782,932 | $6.37M | -$433.2K | 19 | 2026-03-03 |
| 5 | Jean-Jacques Charhon | EVP, CFO | 706,478 | $5.74M | $0 | 4 | 2026-03-03 |
| 6 | Aimee J. Lenar | President, US Pharma | 334,853 | $2.72M | -$258.9K | 8 | 2026-08-20 |
| 7 | Amy B Wechsler | Director | 316,158 | $2.57M | -$350.8K | 42 | 2026-10-02 |
| 8 | Robert N Power | Director | 300,594 | $2.44M | $0 | 8 | 2026-05-26 |
| 9 | Sarah B Kavanagh | Director | 282,230 | $2.29M | $0 | 8 | 2026-05-26 |
| 10 | Steven D Miller | Director | 239,224 | $1.94M | $1.45M | 15 | 2025-05-20 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
BHC Board & Officers
As of SEC filings through Oct 2, 2026Directors 10
- Robert N Power · since Jan 1, 2010
- Amy B Wechsler · since Jun 14, 2016
- Sarah B Kavanagh · since Jul 22, 2016
- John Paulson · since Jun 14, 2017
- Richard Mulligan · since May 10, 2022
- Thomas Appio · listed since May 2022
- Christian A Garcia · since May 14, 2024
- Frank D. Lee · since May 14, 2024
- Sandra Leung · since Jul 22, 2025
- Eiry Roberts · since May 19, 2026
Officers 5
- Thomas Appio · Chief Executive Officer · listed since May 2022
- Aimee J. Lenar · President, US Pharma · listed since Jul 2026
- Jean-Jacques Charhon · EVP, CFO · since Aug 19, 2024
- Seana Carson · EVP, General Counsel · since May 10, 2022
- Steven Hyosig Lee · SVP, Controller & CAO · since Jul 14, 2025
10% owners 1
- Paulson & Co. Inc. (entity) · since Aug 14, 2025
Changes in the last 10 years (50)
| Jul 17, 2026 | Aimee J. Lenar listed as President, US Pharma (previously EVP, US Pharma) in SEC filings |
| Jun 26, 2026 | The company announced the departure of Michael Goettler from the board in an SEC filing |
| May 19, 2026 | Eiry Roberts became a director |
| Aug 14, 2025 | The company announced the departure of Steven D Miller from the board in an SEC filing |
| Aug 14, 2025 | The company announced the departure of Brett Icahn from the board in an SEC filing |
| Aug 14, 2025 | Paulson & Co. Inc. became a 10% owner |
| Jul 22, 2025 | Sandra Leung became a director |
| Jul 22, 2025 | Michael Goettler became a director |
| Jul 14, 2025 | Steven Hyosig Lee became SVP, Controller & CAO |
| May 9, 2025 | The company announced the departure of John S Barresi as SVP, Controller & CAO in an SEC filing |
| Aug 19, 2024 | Jean-Jacques Charhon became EVP, CFO |
| Jul 15, 2024 | Aimee J. Lenar became EVP, US Pharma |
| May 14, 2024 | Frank D. Lee became a director |
| May 14, 2024 | Christian A Garcia became a director |
| Jan 29, 2024 | The company announced the departure of Thomas W. Ross Sr. from the board in an SEC filing |
| Jan 29, 2024 | The company announced the departure of Russel C Robertson from the board in an SEC filing |
| Sep 18, 2023 | The company announced the departure of Tom George Vadaketh as EVP, Chief Financial Officer in an SEC filing |
| Feb 28, 2023 | The company announced the departure of Richard U De Schutter from the board in an SEC filing |
| Feb 28, 2023 | The company announced the departure of Argeris N Karabelas from the board in an SEC filing |
| Jun 23, 2022 | The company announced the departure of Joseph C Papa from the board in an SEC filing |
| Jun 20, 2022 | John S Barresi became SVP, Controller & CAO |
| May 12, 2022 | Thomas Appio listed as Chief Executive Officer (previously CEO, Pharma Business) in SEC filings |
| May 12, 2022 | Thomas Appio first listed as a director in an SEC filing |
| May 10, 2022 | Tom George Vadaketh became EVP, Chief Financial Officer |
| May 10, 2022 | Seana Carson became EVP, General Counsel |
| May 10, 2022 | Richard Mulligan became a director |
| Mar 4, 2022 | Robert Spurr no longer listed as a director in SEC filings |
| Mar 2, 2022 | Robert Spurr first listed as a director in an SEC filing |
| Dec 30, 2021 | Thomas Appio listed as CEO, Pharma Business (previously Pres&Co-Head Bausch&Lomb/Int'l) in SEC filings |
| Oct 5, 2021 | Robert Spurr listed as U.S. President-Pharma Business (previously President, Salix) in SEC filings |
| Jun 3, 2021 | Sam Eldessouky listed as EVP & Chief Financial Officer (previously SVP, Chief Accounting Officer) in SEC filings |
| Jun 1, 2021 | Frederick Munsch became SVP, Controller and CAO |
| Mar 17, 2021 | Steven D Miller became a director |
| Mar 17, 2021 | Brett Icahn became a director |
| May 27, 2020 | Robert Spurr became President, Salix |
| Jan 10, 2019 | Joseph F Gordon listed as Pres&Co-Head Bausch&Lomb/Int'l (previously President Bausch & Lomb/Int'l) in SEC filings |
| Jan 7, 2019 | William D. Humphries listed as President, Ortho-Dermatologics (previously EVP, Company Group Chairman) in SEC filings |
| Oct 29, 2018 | Andrew C. Von Eschenbach became a director |
| Aug 22, 2018 | Thomas Appio listed as Pres&Co-Head Bausch&Lomb/Int'l (previously EVP, Company Group Chairman) in SEC filings |
| Aug 2, 2018 | Mark C. McKenna became President, Salix |
| Aug 2, 2018 | Joseph F Gordon became President Bausch & Lomb/Int'l |
| May 3, 2018 | Fredric N Eshelman reported in an SEC filing no longer being a director |
| Jun 14, 2017 | John Paulson became a director |
| May 3, 2017 | William A Ackman reported in an SEC filing no longer being a director |
| May 3, 2017 | Stephen Fraidin reported in an SEC filing no longer being a director |
| May 3, 2017 | Pershing Square Capital Management, L.P. reported in an SEC filing no longer being a director |
| May 3, 2017 | PS Management GP, LLC reported in an SEC filing no longer being a director |
| Jan 2, 2017 | William D. Humphries became EVP, Company Group Chairman |
| Jan 2, 2017 | Richard U De Schutter became a director |
| Nov 8, 2016 | Robert L. Rosiello listed as EVP, Corp Dev & Strategy (previously EVP, Chief Financial Officer) in SEC filings |
Not reported recently (14)
- Robert Spurr · Last reported as U.S. President-Pharma Business in an SEC filing dated May 12, 2022
- Frederick Munsch · Last reported as SVP, Controller and CAO in an SEC filing dated May 5, 2022
- Christina Ackermann · Last reported as EVP and General Counsel in an SEC filing dated Mar 11, 2022
- Joseph F Gordon · Last reported as Pres&Co-Head Bausch&Lomb/Int'l in an SEC filing dated Mar 10, 2022
- Joseph C Papa · Last reported as Chairman & CEO in an SEC filing dated Mar 7, 2022
- Sam Eldessouky · Last reported as EVP & Chief Financial Officer in an SEC filing dated Mar 7, 2022
- Andrew C. Von Eschenbach · Last reported as a director in an SEC filing dated Aug 9, 2021
- Paul Herendeen · Last reported as EVP and CFO in an SEC filing dated Mar 10, 2021
- William D. Humphries · Last reported as President, Ortho-Dermatologics in an SEC filing dated Dec 8, 2020
- Mark C. McKenna · Last reported as President, Salix in an SEC filing dated Aug 21, 2019
- Robert Alexander Ingram · Last reported as a director in an SEC filing dated Apr 4, 2017
- Anne Clem Whitaker · Last reported as EVP, Company Group Chairman in an SEC filing dated Dec 20, 2016
- Ari Kellen · Last reported as EVP, Company Group Chairman in an SEC filing dated Dec 7, 2016
- Robert L. Rosiello · Last reported as EVP, Corp Dev & Strategy in an SEC filing dated Dec 7, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
BHC Proposed Insider Sales (Form 144)
Latest: 2026-08-19
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $259K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Lenar Aimee J. (1, $259K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | Lenar Aimee J. | Officer | 36,827 | $258.9K | 2026-08-19 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-05-19 | Lee Frank D. | Director | 24,456 | $132.8K | 2026-05-19 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-03-03 | Carson Seana | Officer | 4,420 | $25.5K | 2026-03-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-03-02 | Carson Seana | Officer | 6,856 | $39.6K | 2026-03-02 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-02-27 | Carson Seana | Officer | 8,388 | $49.9K | 2026-02-27 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-09-08 | Carson Seana | Officer | 13,370 | $97.7K | 2025-09-08 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-08-21 | Lee Frank D. | Director | 15,912 | $121.9K | 2025-08-21 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-12-02 | Carson Seana | Officer | 440 | $3.7K | 2024-12-02 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-09-06 | Carson Seana | Officer | 13,370 | $83.0K | 2024-09-06 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-03-04 | Carson Seana | Officer | 6,313 | $61.9K | 2024-03-04 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
24 ETFs hold BHC
24 shown · $79.81M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXUS Vanguard Total International Stock ETF | Vanguard | 0.00% | $21.9M | — | 2026-09-30 |
| 2 | VEA Vanguard FTSE Developed Markets ETF | Vanguard | 0.00% | $14.4M | — | 2026-09-30 |
| 3 | FNDF Schwab Fundamental International Equity ETF | Nport | 0.04% | $10.3M | — | 2026-08-31 |
| 4 | VSS Vanguard FTSE All-World EX-US Small-Cap Index Fund | Vanguard | 0.04% | $5.5M | — | 2026-09-30 |
| 5 | SPDW State Street® SPDR® Portfolio Developed World ex-US ETF | SPDR (State Street) | 0.01% | $3.4M | $41.2B | 2026-11-04 |
| 6 | IDEV iShares Core MSCI International Developed Markets ETF | iShares (BlackRock) | 0.01% | $3.3M | $33.7B | 2026-11-04 |
| 7 | FDLS Inspire Fidelis Multi Factor ETF | Nport | 1.29% | $3.2M | — | 2026-08-31 |
| 8 | IXUS iShares Core MSCI Total International Stock ETF | iShares (BlackRock) | 0.01% | $3.2M | $56.4B | 2026-11-04 |
| 9 | SCHC Schwab International Small-Cap Equity ETF | Nport | 0.05% | $2.9M | — | 2026-05-31 |
| 10 | DFIS Dimensional International Small Cap ETF | Dimensional | 0.05% | $2.8M | $5.8B | 2026-11-04 |
| 11 | DFIC Dimensional International Core Equity 2 ETF | Dimensional | 0.01% | $1.8M | $15.4B | 2026-11-04 |
| 12 | DISV Dimensional International Small Cap Value ETF | Dimensional | 0.04% | $1.8M | $5.1B | 2026-11-04 |
| 13 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $1.2M | — | 2026-09-30 |
| 14 | DFAX Dimensional World ex US Core Equity 2 ETF | Dimensional | 0.01% | $835,918 | $12.0B | 2026-11-04 |
| 15 | PXF Invesco RAFI Developed Markets ex-U.S. ETF | Nport | 0.03% | $783,777 | — | 2026-07-31 |
| 16 | ISCF iShares International Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.10% | $729,650 | $705.0M | 2026-11-04 |
| 17 | TLTD FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund | Nport | 0.08% | $536,860 | — | 2026-07-31 |
| 18 | VSGX Vanguard ESG International Stock ETF | Vanguard | 0.01% | $439,044 | — | 2026-11-04 |
| 19 | DFAI Dimensional International Core Equity Market ETF | Dimensional | 0.00% | $260,341 | $18.3B | 2026-11-04 |
| 20 | WSML iShares MSCI World Small-Cap ETF | iShares (BlackRock) | 0.02% | $141,224 | $657.0M | 2026-11-04 |
| 21 | DFSI Dimensional International Sustainability Core 1 ETF | Dimensional | 0.01% | $116,168 | $1.2B | 2026-11-04 |
| 22 | DTAN Sparkline International Intangible Value ETF | Nport | 0.38% | $85,084 | — | 2026-08-31 |
| 23 | DXIV Dimensional International Vector Equity ETF | Dimensional | 0.03% | $66,245 | $237.2M | 2026-11-04 |
| 24 | SPGM State Street® SPDR® Portfolio MSCI Global Stock Market ETF | SPDR (State Street) | 0.00% | $8,172 | $1.8B | 2026-11-04 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.28
TTM Revenue
$11.11B
TTM Net Income
$-841.00M
TTM Op. Cash Flow
$2.21B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $2.94B | $436.00M | $1.15 | $814.00M |
| Q2 '26 | 2026-06-30 | $2.85B | $258.00M | $0.68 | $670.00M |
| Q1 '26 | 2026-03-31 | $2.52B | $-1.42B | $-3.82 | $230.00M |
| Q4 '25 | 2025-12-31 | $2.80B | $-112.00M | $-0.30 | $495.00M |
| Q3 '25 | 2025-09-30 | $2.68B | $179.00M | $0.48 | $405.00M |
| Q2 '25 | 2025-06-30 | $2.53B | $148.00M | $0.40 | $289.00M |
| Q1 '25 | 2025-03-31 | $2.26B | $-58.00M | $-0.16 | $211.00M |
| Q4 '24 | 2024-12-31 | $2.56B | $93.00M | $0.25 | $601.00M |
| Q3 '24 | 2024-09-30 | $2.51B | $-85.00M | $-0.23 | $405.00M |
| Q2 '24 | 2024-06-30 | $2.40B | $10.00M | $0.03 | $380.00M |
| Q1 '24 | 2024-03-31 | $2.15B | $-64.00M | $-0.17 | $211.00M |
| Q4 '23 | 2023-12-31 | $2.41B | $-39.00M | $-0.10 | $390.00M |
Q3 2026 • period ending 2026-09-30 • filed 2026-10-29
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
0.28
EV/EBITDA
5.41
EV/Sales
1.95
ROE
—
ROA
-4.4%
Div Yield
0.00%
FCF Yield
58.92%
Debt/Equity
—
Current Ratio
—
Market Cap
$3.06B
as of 2026-11-06
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
8.24M
SI % of Float
3.12%
Days to Cover
4.17
Short Vol Ratio
18.2%
Free Float
264.25M
Float %
70.6%
Short interest 2026-10-15 • Short volume 2026-11-05 • Float 2026-10-02